Paclib Use In Pregnancy & Lactation

Pregnancy: 5 mL & 16.67 mL: Category D.
Paclitaxel can cause fetal harm when administered to pregnant women. Women who are pregnant or those wanting to become pregnant should be advised to avoid becoming pregnant during paclitaxel therapy. Paclitaxel should be used only when clearly needed and when potential benefits outweigh the unknown hazards to the baby.
43.4 mL: Paclitaxel (Paclib) has been shown to be fetotoxic and to decrease fertility in animal studies.
There is no information on the use of Paclitaxel (Paclib) in pregnant women. Paclitaxel (Paclib) may cause fetal harm when administered to pregnant women.
Paclitaxel (Paclib) should not be used during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Paclitaxel (Paclib), and to inform the treating physician immediately should this occur.
Breastfeeding: 5 mL & 16.67 mL: It is not known whether paclitaxel is distributed to human milk. Breastfeeding is not recommended during chemotherapy because of the potential serious adverse reactions to paclitaxel by the breastfeeding infant.
43.4 mL: It is not known whether Paclitaxel (Paclib) is excreted in human milk. Breast feeding should be discontinued for the duration of Paclitaxel (Paclib) therapy.